« Back
Home /
THZ1 (Hydrochloride)

THZ1 (Hydrochloride)

Item no.	HY-80013A-5mg
Manufacturer	MedChem Express
Amount	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	99.06
Formula	C31H29Cl2N7O2
Citations	Breast Cancer Res. 2023 May 5;25(1):51. Cancer Discov. 2019 Nov;9(11):1538-1555. Drug Dev Res. 2025 Feb;86(1):e70049. Front Oncol. 2021 Apr 6;11:663360. Harvard Medical School LINCS LIBRARY Int J Biol Sci. 2019 Jun 10;15(8):1733-1742. Mol Cell. 2019 May 16;74(4):674-687.e11. Nat Commun. 2018 Nov 19;9(1):4866. Nat Commun. 2018 Aug 23;9(1):3392. Nat Med. 2019 Feb;25(2):292-300. Oncotarget. 2017 Apr 18;8(16):27353-27363. Patent. US20220288067A1. Research Square Print. 2022 May. Acta Pharmacol Sin. 2019 Jun;40(6):814-822. Autophagy. 2021 Jun;17(6):1426-1447. Biochem Biophys Res Commun. 2023 Nov 7, 149188. Biochim Biophys Acta Mol Cell Res. 2019 Jun;1866(6):978-991. bioRxiv. 2019 Oct. bioRxiv. 2024 July 12. bioRxiv. 2024 July 27. bioRxiv. June 18, 2021. Cancer Immunol Res. 2021 Apr 19. Cancer Lett. 2021 Mar 16;S0304-3835(21)00117-8. Cancer Lett. 2024 Mar 13:216811. Cancer Res. 2021 Jun 1;81(11):3105-3120. Cancers (Basel). 2022, 14(11), 2755. Cell Commun Signal. 2022 Sep 5;20(1):96. Cell Death Differ. 2023 Feb 24. Cell Death Dis. 2020 Sep 15;11(9):754. Cell Death Dis. 2021 Aug 3;12(8):763. Cell Death Dis. 2021 Mar 3;12(3):229. Cell Death Dis. 2019 Aug 9;10(8):602. Cell Oncol. 2021 Apr 27. Cell Rep Med. 2023 Mar 31;101007. Cell Rep. 2022 Apr 26;39(4):110732. Cell. 2017 Sep 7;170(6):1209-1223.e20. Cell. 2018 Sep 20;175(1):171-185.e25. Cells. 2019 Oct 6;8(10):1208. Cells. 2020 Mar 6;9(3):638. Cells. 2021 May 12;10(5):1182. Cells. 2020 Mar 4;9(3):621. Chinese Medical Journal. 2022. Clin Cancer Res. 2019 Oct 15;25(20):6195-6205. EMBO Mol Med. 2022 Mar 7;e14990. Eur J Pharmacol. 2023 Jul 8;175892. FEBS J. 2024 May 11. Front Mol Biosci. 2021 Aug 19;8:697457. Front Oncol. 2021 May 24;11:664848. Genes Dev. 2020 Jan 1;34(1-2):53-71. Harvard Medical School LINCS LIBRARY Heliyon. 2024 Jan 9. Hepatology. 2019 Jun;69(6):2502-2517. iScience. 2024 May 16. IUBMB Life. 2021 Oct 30. J Exp Clin Cancer Res. 2021 Apr 26;40(1):141. J Exp Clin Cancer Res. 2022 Aug 10;41(1):241. J Exp Clin Cancer Res. 2022 Oct 22;41(1):311. J Exp Clin Cancer Res. 2023 Aug 21;42(1):214. J Invest Dermatol. 2021 May 15;S0022-202X(21)01232-X. J Med Chem. 2022 Nov 17. J Mol Neurosci. 2021 Aug 31. Mol Cancer Ther. 2017 Sep;16(9):1739-1750. Nat Cell Biol. 2020 Oct;22(10):1187-1196. Nat Commun. 2019 Jul 25;10(1):3319. Nat Commun. 2024 Aug 9;15(1):6810. Nat Commun. 2025 Feb 2;16(1):1271. Onco Targets Ther. 2019 Mar 22;12:2137-2147. Oncogene. 2019 May;38(20):3932-3945. Oncogene. 2022 Aug 30. Oncogenesis. 2017 May 15;6(5):e336. Oncogenesis. 2020 May 12;9(5):47. PLoS Pathog. 2024 Apr 19;20(4):e1012138. Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12986-12995. Regen Biomater. 2024 Mar 1. Research Square Preprint. 2022 Feb. Research Square Preprint. 2022 Jan. Research Square Print. September 29th, 2022. Sci Adv. 2020 Jul 17;6(29):eaba1593. Sci Rep. 2024 May 8;14(1):10582. Science. 2021 Apr 30;372(6541):eaba8490. TUMOR, 2017, 37(11): 1119-1127. Universidade de Lisboa. 2021 Dec 21. University of London. 2022 May. [1]Kwiatkowski N, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31;511(7511):616-20. [2]Jiang YY, et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut. 2016 May 10. pii: gutjnl-2016-311818. [3]Christensen CL, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014 Dec 8;26(6):909-22. [4]Chipumuro, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014 Nov 20;159(5):1126-39. ?
Smiles	ClC1=CN=C(NC2=CC(NC(C3=CC=C(NC(/C=C/CN(C)C)=O)C=C3)=O)=CC=C2)N=C1C4=CNC5=CC=CC=C54.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CDK7 inhibitor
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	CDK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	602.51
Product Description	THZ1 Hydrochloride is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM. THZ1 Hydrochloride also inhibits the closely related kinases CDK12 and CDK13 and downregulates MYC expression[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO : 116.67 mg/mL (ultrasonic)\|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Cell Cycle/DNA Damage
Isoform	CDK12; CDK13; CDK7
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-80013A-5mg-safety-datasheet.pdf